Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ritobegron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 known ✓ | P13945 | 7/20 | 0.64 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | GALR3 | O60755 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ritobegron SCHEMBL5916906 | 1.00 | ADRB3 (0.64) | ADRB3ADRB2LMNASLC6A2SLC6A4 | |
| Ritobegron SCHEMBL4186380 | 1.00 | ADRB3 (0.64) | ADRB3ADRB2LMNASLC6A2SLC6A4 | |
| Ritobegron SCHEMBL1404072 | 1.00 | ADRB3 (0.64) | ADRB3ADRB2LMNASLC6A2SLC6A4 | |
| Ritobegron SCHEMBL2949688 | 0.99 | ADRB3 (0.63) | ADRB3ADRB2LMNASLC6A2SLC6A4 | |
| Ritobegron SCHEMBL2947591 | 0.99 | ADRB3 (0.63) | ADRB3ADRB2LMNASLC6A2SLC6A4 | |
| Ritobegron SCHEMBL2950593 | 0.99 | ADRB3 (0.63) | ADRB3ADRB2LMNASLC6A2SLC6A4 | |
| Ritobegron SCHEMBL2950589 | 0.99 | ADRB3 (0.63) | ADRB3ADRB2LMNASLC6A2SLC6A4 | |
| Ritobegron SCHEMBL4108225 | 0.92 | ADRB3 (0.58) | ADRB3LMNASLC6A2SLC6A4OPRM1 | |
| SCHEMBL13653975 | 0.92 | ADRB3 (0.54) | ADRB3ADRB2LMNASLC6A2SLC6A4 | |
| SCHEMBL13653968 | 0.92 | ADRB3 (0.54) | ADRB3ADRB2LMNASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| US-20240374557-A1 | BETA ADRENERGIC RECEPTOR COMPOSITIONS AND METHODS OF USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-11-14 | — | — | US | claimed |
| US-20240148701-A1 | WOULD HEALING METHODS | UNIV SYDNEY (AU) | 2024-05-09 | — | — | US | claimed |
| EP-4294390-A1 | WOUND HEALING METHODS | The University Of Sydney (AU) | 2023-12-27 | — | — | EP | claimed |
| WO-2023192319-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA (US) | 2023-10-05 | — | — | WO | claimed |
| WO-2023028602-A1 | BETA ADRENERGIC RECEPTOR COMPOSITIONS AND METHODS OF USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-03-02 | — | — | WO | claimed |
| WO-2022198259-A1 | TREATMENT METHODS FOR PULMONARY ARTERIAL HYPERTENSION | THE HEART RESEARCH INSTITUTE LTD (AU) | 2022-09-29 | — | — | WO | claimed |
| WO-2022174309-A1 | WOUND HEALING METHODS | THE UNIVERSITY OF SYDNEY (AU) | 2022-08-25 | — | — | WO | claimed |
| US-20100197788-A9 | Preventive or therapeutic agent for disease caused by decrease in lacrimal fluid | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-08-05 | — | — | US | claimed |
| EP-1728508-B1 | MEDICINE FOR PREVENTION OR TREATMENT OF FREQUENT URINATION OR URINARY INCONTINENCE | KISSEI PHARMACEUTICAL (JP) | 2009-09-09 | — | — | EP | claimed |
| US-20050261328-A1 | Pharmaceutical composition comprising beta-3-adrenoceptor-agonists and antimuscarinic agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | US | claimed |
| US-20050261369-A1 | Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | US | claimed |
| US-20050154041-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and alpha-agonist | BOEHRINGER INGELHEIN INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | claimed |
| US-20050119239-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and an active substance which influences prostaglandin metabolism | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-06-02 | — | — | US | claimed |
| US-20050101607-A1 | Pharmaceutical composition containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha reductase inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-12 | — | — | US | claimed |
| WO-2004098586-A1 | USE OF PHENOXYACETIC ACID DERIVATIVES FOR TREATING HYPERACTIVE BLADDER | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-18 | — | — | WO | claimed |
| US-20040229947-A1 | Method of treating hyperactive bladder using phenoxyacetic acid derivatives | KISSEI PHARMACEUTICAL CO., LTD. | 2004-11-18 | — | — | US | claimed |
| EP-1095932-B1 | PHENOXYACETIC ACID DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | KISSEI PHARMACEUTICAL (JP) | 2004-05-19 | — | — | EP | claimed |
| US-6538152-B1 | Obesity, hyperglycemia, urinary incontinence, intestinal or biliary calculi hypermotility, pollakiuria and depression treatment | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2003-03-25 | — | — | US | claimed |
| EP-1095932-A1 | PHENOXYACETIC ACID DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2001-05-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101607-A1 | Pharmaceutical composition containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha reductase inhibitor | ADRB1, ADRB3, ADRB2 | ADRB3 2/4885ADRB2 3/4885LMNA 2502/4885 |
| US-20050261369-A1 | Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB2 2/4885LMNA 1918/4885 |
| US-20050154041-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and alpha-agonist | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB2 2/4885LMNA 1686/4885 |
| US-20050261328-A1 | Pharmaceutical composition comprising beta-3-adrenoceptor-agonists and antimuscarinic agents | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB2 2/4885LMNA 2025/4885 |
| US-20040229947-A1 | Method of treating hyperactive bladder using phenoxyacetic acid derivatives | BPHL, HTR5A, PNMT | ADRB3 123/4885ADRB2 96/4885LMNA 4385/4885 |
| US-20050119239-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and an active substance which influences prostaglandin metabolism | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB2 2/4885LMNA 1785/4885 |
| US-20240148701-A1 | WOULD HEALING METHODS | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB2 2/4885LMNA 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.